Strong Revenue Growth
Bavarian Nordic recorded almost DKK1.4 billion in revenue, representing a 62% growth compared to the previous year.
EBITDA Margin Achievement
The company established an EBITDA margin of 31%, indicating a strong start to the year.
Travel Health Sales Surge
Travel health segment showed a 52% growth, driven by rabies and TBE vaccines, with rabies growing by 53% and TBE by 62%.
Chikungunya Vaccine Launch
Bavarian Nordic launched its Chikungunya vaccine, VIMKUNYA, which has been approved in the U.S., Europe, and the U.K., with initial sales recorded.
New Order from U.S. Government
A new order from the U.S. government (BARDA) for $144 million was secured, increasing existing contracts from DKK2.5 billion to DKK2.65 billion.
Gross Margin Improvement
Achieved a gross margin of 51%, two percentage points better than last year's full-year performance.
Future Growth in Travel Health
The travel health market is expected to grow at a 20% CAGR, with Bavarian Nordic well-positioned due to expanding endemic regions and new vaccine introductions.